Polyrizon (PLRZ) Competitors $0.36 0.00 (-1.19%) As of 04/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PLRZ vs. PRPH, TXMD, SLXN, TSBX, PHIO, RLMD, NEUP, BCLI, NKGN, and APLMShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include ProPhase Labs (PRPH), TherapeuticsMD (TXMD), Silexion Therapeutics (SLXN), Turnstone Biologics (TSBX), Phio Pharmaceuticals (PHIO), Relmada Therapeutics (RLMD), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Brainstorm Cell Therapeutics (BCLI), NKGen Biotech (NKGN), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. ProPhase Labs TherapeuticsMD Silexion Therapeutics Turnstone Biologics Phio Pharmaceuticals Relmada Therapeutics Neuphoria Therapeutics Inc. - Common Stock Brainstorm Cell Therapeutics NKGen Biotech Apollomics Polyrizon (NASDAQ:PLRZ) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability. Does the MarketBeat Community prefer PLRZ or PRPH? ProPhase Labs received 114 more outperform votes than Polyrizon when rated by MarketBeat users. CompanyUnderperformOutperformPolyrizonN/AN/AProPhase LabsOutperform Votes11448.93% Underperform Votes11951.07% Is PLRZ or PRPH more profitable? Polyrizon has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. Polyrizon's return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A ProPhase Labs -217.64%-62.92%-30.22% Which has stronger earnings and valuation, PLRZ or PRPH? Polyrizon has higher earnings, but lower revenue than ProPhase Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/AN/AN/AN/AProPhase Labs$12.75M0.76-$16.78M-$1.26-0.32 Does the media favor PLRZ or PRPH? In the previous week, Polyrizon had 3 more articles in the media than ProPhase Labs. MarketBeat recorded 11 mentions for Polyrizon and 8 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.62 beat Polyrizon's score of 0.37 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in PLRZ or PRPH? 9.4% of ProPhase Labs shares are owned by institutional investors. 20.7% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryProPhase Labs beats Polyrizon on 5 of the 9 factors compared between the two stocks. Remove Ads Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53M$6.76B$5.54B$7.86BDividend YieldN/A2.80%5.35%4.04%P/E RatioN/A7.0923.4018.67Price / SalesN/A199.58369.3087.31Price / CashN/A65.6738.1634.64Price / BookN/A5.966.624.09Net IncomeN/A$142.11M$3.20B$246.93M7 Day Performance-22.43%-7.58%-5.00%-3.16%1 Month Performance-51.82%-12.54%-1.57%-6.74%1 Year PerformanceN/A-13.53%8.66%-0.49% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$0.36-1.2%N/AN/A$1.53MN/A0.00N/AGap DownPRPHProPhase Labs1.7757 of 5 stars$0.40+2.0%N/A-94.1%$9.52M$12.75M-0.32130News CoverageGap UpTXMDTherapeuticsMD0.8863 of 5 stars$0.82+10.4%N/A-57.8%$9.46M$1.60M0.00420Upcoming EarningsAnalyst ForecastShort Interest ↓SLXNSilexion TherapeuticsN/A$1.11-11.2%$9.00+710.8%N/A$9.34MN/A0.00N/ATSBXTurnstone Biologics1.7231 of 5 stars$0.40+2.5%$0.45+11.4%-86.8%$9.34M$19.31M-0.1282Earnings ReportPHIOPhio Pharmaceuticals2.61 of 5 stars$1.35-2.9%$4.00+196.3%-79.5%$9.30MN/A-0.1210Upcoming EarningsRLMDRelmada Therapeutics3.8868 of 5 stars$0.30+1.4%$4.25+1,316.2%-94.4%$9.06MN/A-0.1010Earnings ReportNEUPNeuphoria Therapeutics Inc. - Common Stock1.81 of 5 stars$5.07+3.5%$21.00+314.2%N/A$8.91M$662,715.000.00N/AGap UpBCLIBrainstorm Cell Therapeutics3.8212 of 5 stars$1.56+0.6%$30.00+1,823.1%-89.3%$8.90MN/A-0.3340Earnings ReportUpcoming EarningsNews CoverageGap UpNKGNNKGen BiotechN/A$0.19+7.0%N/A-91.4%$8.66M$80,000.00-0.04N/AGap DownAPLMApollomics2.5592 of 5 stars$7.96flat$200.00+2,412.6%-89.8%$8.65M$1.22M0.0045Gap Up Remove Ads Related Companies and Tools Related Companies ProPhase Labs Alternatives TherapeuticsMD Alternatives Silexion Therapeutics Alternatives Turnstone Biologics Alternatives Phio Pharmaceuticals Alternatives Relmada Therapeutics Alternatives Neuphoria Therapeutics Inc. - Common Stock Alternatives Brainstorm Cell Therapeutics Alternatives NKGen Biotech Alternatives Apollomics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredOil Surge Predicted... But Are You Ready?Do you own oil and gas stocks? Or are you thinking about buying some? But it's NOT oil stocks, futures, or ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
